Amrubicin therapy improves patients with refractory small-cell lung cancer: A single-arm confirmatory Chinese clinical study

Abstract

<p class="Abstract">Our objective was to evaluate an open-label, multicenter, single-arm study to appraise whether amrubicin therapy improves patients with refractory small-cell lung cancer in Chinese clinical study. Patients (n=95) with refractory small-cell lung cancer received 3 consecutive days amrubicin therapy for 21 days. Overall response rate of response to amrubicin was 39%. Anemia, febrile neutropenia, thrombocytopenia, hyperglycemia, hyponatremia, infection, elevated serum transaminases levels were appeared, but the incidences of adverse events were very few. Our results suggest amrubicin therapy can improve patients with refractory small-cell lung cancer and may be an effective and safe treatment option.</p><p> </p>

The Evolving Scenario of ES-SCLC Management: From Biology to New Cancer Therapeutics

“…However, similar to the other chemotherapeutics, lurbinectedin performed best in patients with CT-sensitive disease [ 54 ]. The results from other chemotherapeutics (topoisomerase I inhibitors, alkylating agents, antimetabolites, new platinum compounds, taxanes) and formulations were even more disappointing, both in terms of efficacy and/or toxicity [ 121 , 122 , 123 , 124 , 125 , 126 , 127 , 128 , 129 , 130 , 131 , 132 , 133 , 134 , 135 , 136 , 137 , 138 ].…”

“…In 2002, amrubicin, a third-generation synthetic anthracycline, was approved in Japan based on efficacy data from a phase II trial in both SCLC and NSCLC [ 132 ]. Another two phase II trials have shown a modest activity of amrubicin in a Chinese patient population [ 133 ] and with a weekly dosing schedule in a Japanese population [ 134 ]. However, this drug is not available around the world outside Japan.…”